drugset / Trial / NCT04050163

MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)

NCT04050163

Non-randomizedSequentialSingle-blindTreatment

Summary

The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)

Timeline

Start
2021-01-26
Primary completion
2023-05-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy 0.5 cells/kg Intravenous
Subject Rexlemestrocel-L Cell therapy 1.6 cells/kg Intravenous
Subject Rexlemestrocel-L Cell therapy 5 cells/kg Intravenous

Indications